PT-141 (Bremelanotide)
FDA approvedAlso known as: Vyleesi
FDA-approved melanocortin agonist — sexual desire treatment that bypasses vascular pathways.
Mechanism
Melanocortin receptor agonist. FDA-approved melanocortin agonist — sexual desire treatment that bypasses vascular pathways. For full mechanism, dosing protocol, and stacking guidance, ask the AI Advisor or open the compound in-app.
Peer-Reviewed Studies (2)
Bremelanotide for HSDD in Premenopausal Women (RECONNECT)
Two phase 3 RCTs: significant improvement in desire.
PubMed PMID 31135730 →Bremelanotide Mechanism Review
Reviews central mechanism vs flibanserin and PDE5 inhibitors.
PubMed PMID 32008979 →